Orexo Capital Markets Day May 3, 2012
Orexo will conduct a Capital Markets Day on Thursday, May 3, 2012. The event, that addresses in particular analysts, investors and media, starts at 2:00pm and will be held at the company premises at Virdings allé 32 A in Uppsala.
Detailed program will be available closer to the event at www.orexo.com, where registration also can be made. Limited number of seats.
For further information, please contact:
Beata Augenblick, Investor Relations
Phone: +46 18-780 88 50
Orexo develops and markets pharmaceuticals based on proprietary drug delivery technologies applied to well-known substances. The company's largest product is Abstral, a treatment of breakthrough cancer pain. Orexo’s shares are listed on the Stockholm Stock Exchange and Danish Novo A/S and Swedish HealthCap are the largest shareholders. More information can be found at www.orexo.com
|Note: This is information that Orexo AB (publ) discloses pursuant to the Financial Instruments Trading Act and/or Securities Market Act. The information was provided for public release on March 27, 2012 at 10.00 CET. This press release has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall take precedence.